Source 1primary paper2026MED
Toolkit/TIL
TIL
Also known as: TILs, tumor-infiltrating lymphocytes
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Significant advances have been made in recent years in the development of CAR-T cells, T cell receptor-engineered T cells (TCR-T), and tumor-infiltrating lymphocytes (TILs) for solid tumors.
Usefulness & Problems
Why this is useful
TIL therapy is presented as one of the major T cell immunotherapy modalities being developed for solid tumors.; T cell immunotherapy for solid tumors
Source:
TIL therapy is presented as one of the major T cell immunotherapy modalities being developed for solid tumors.
Source:
T cell immunotherapy for solid tumors
Problem solved
It contributes to the effort to bring effective T cell-based treatment into solid tumors.; Provides a T cell-based therapeutic modality for solid tumors
Source:
It contributes to the effort to bring effective T cell-based treatment into solid tumors.
Source:
Provides a T cell-based therapeutic modality for solid tumors
Problem links
Provides a T cell-based therapeutic modality for solid tumors
LiteratureIt contributes to the effort to bring effective T cell-based treatment into solid tumors.
Source:
It contributes to the effort to bring effective T cell-based treatment into solid tumors.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
No mechanism tags yet.
Techniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
Clinical translation must address solid-tumor biological and technical barriers
The abstract does not state that TILs alone solve antigen heterogeneity, suppressive TME, or persistence limitations.; Field-wide solid-tumor barriers include suppressive TME and insufficient T cell persistence
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Antigen escape, on-target off-tumor toxicity, and suppressive tumor microenvironment features are important biological and technical challenges that impede treatment efficacy in solid-tumor T cell immunotherapy.
Particular attention is given to the biological and technical challenges that impede treatment efficacy, including antigen escape, on-target off-tumor toxicity, and the suppressive features of the TME.
CAR-T cells have achieved notable success in hematological malignancies.
T cell-based immunotherapies have achieved notable success in the treatment of hematological malignancies, particularly through the application of chimeric antigen receptor (CAR) T cells.
The clinical efficacy of T cell-based immunotherapies in solid tumors remains limited by tumor antigen heterogeneity, immunosuppressive tumor microenvironment, and insufficient T cell infiltration and persistence.
However, the clinical efficacy of such approaches in solid tumors remains limited due to a range of intrinsic and extrinsic barriers, including tumor antigen heterogeneity, the immunosuppressive tumor microenvironment (TME), and insufficient T cell infiltration and persistence.
Significant advances have been made in the development of CAR-T, TCR-T, and TIL therapies for solid tumors.
Despite these challenges, significant advances have been made in recent years in the development of CAR-T cells, T cell receptor-engineered T cells (TCR-T), and tumor-infiltrating lymphocytes (TILs) for solid tumors.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug til
Significant advances have been made in recent years in the development of CAR-T cells, T cell receptor-engineered T cells (TCR-T), and tumor-infiltrating lymphocytes (TILs) for solid tumors.
Source:
challengesupports
Antigen escape, on-target off-tumor toxicity, and suppressive tumor microenvironment features are important biological and technical challenges that impede treatment efficacy in solid-tumor T cell immunotherapy.
Particular attention is given to the biological and technical challenges that impede treatment efficacy, including antigen escape, on-target off-tumor toxicity, and the suppressive features of the TME.
Source:
limitationsupports
The clinical efficacy of T cell-based immunotherapies in solid tumors remains limited by tumor antigen heterogeneity, immunosuppressive tumor microenvironment, and insufficient T cell infiltration and persistence.
However, the clinical efficacy of such approaches in solid tumors remains limited due to a range of intrinsic and extrinsic barriers, including tumor antigen heterogeneity, the immunosuppressive tumor microenvironment (TME), and insufficient T cell infiltration and persistence.
Source:
progresssupports
Significant advances have been made in the development of CAR-T, TCR-T, and TIL therapies for solid tumors.
Despite these challenges, significant advances have been made in recent years in the development of CAR-T cells, T cell receptor-engineered T cells (TCR-T), and tumor-infiltrating lymphocytes (TILs) for solid tumors.
Source:
Comparisons
Source-stated alternatives
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Source:
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Source-backed strengths
Significant recent advances are noted
Source:
Significant recent advances are noted
Compared with CAR-T
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Significant recent advances are noted.
Relative tradeoffs: Field-wide solid-tumor barriers include suppressive TME and insufficient T cell persistence.
Source:
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Compared with CAR-T cells
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Significant recent advances are noted.
Relative tradeoffs: Field-wide solid-tumor barriers include suppressive TME and insufficient T cell persistence.
Source:
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Compared with CAR-T therapy
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Significant recent advances are noted.
Relative tradeoffs: Field-wide solid-tumor barriers include suppressive TME and insufficient T cell persistence.
Source:
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Significant recent advances are noted.
Relative tradeoffs: Field-wide solid-tumor barriers include suppressive TME and insufficient T cell persistence.
Source:
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Compared with chimeric antigen receptor T cells
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Significant recent advances are noted.
Relative tradeoffs: Field-wide solid-tumor barriers include suppressive TME and insufficient T cell persistence.
Source:
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Compared with Chimeric antigen receptor T-cell therapy
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Significant recent advances are noted.
Relative tradeoffs: Field-wide solid-tumor barriers include suppressive TME and insufficient T cell persistence.
Source:
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Compared with TCR-T
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: Significant recent advances are noted.
Relative tradeoffs: Field-wide solid-tumor barriers include suppressive TME and insufficient T cell persistence.
Source:
The review compares TILs with CAR-T and TCR-T and discusses adjunct strategies such as checkpoint blockade and gene editing.
Ranked Citations
- 1.